ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

Posted on by

Astria Therapeutics is granted global rights to develop and commercialize OX40 portfolio, comprised of Telazorlimab and its follow-on molecules, for use in inflammatory and immune diseases. NEW YORK, Oct. 11, 2023 /PRNewswire/ — Ichnos Sciences, a global clinical-stage biotechnology…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.